The Short Version
Between 2023 and 2024, the FDA declared Wegovy, Ozempic, and Zepbound in shortage, which legally permitted 503A and 503B compounding pharmacies to produce alternative versions. This created a $3-5 billion compounded GLP-1 industry almost overnight. Companies like MEDVi, Hims, and Ro built massive businesses on the cash-pay compounded model.
In 2025, the FDA resolved both the semaglutide and tirzepatide shortages. Compounding under the shortage designation is no longer permitted. Pharmacies are relying on narrower "patient-specific compounding" rules that have attracted significant FDA scrutiny.
In 2026, the landscape looks very different than it did in 2024. Patients on compounded are making decisions about whether to stay or switch. This article explains the regulatory context and the pricing math so you can make an informed choice.
What the FDA Actually Allows
The FDA has two main compounding regulations:
503A compounding (traditional pharmacy compounding)
Licensed pharmacies can compound medications for individual patients with a valid prescription. To compound semaglutide or tirzepatide under 503A rules, the drug must be on one of these lists:
- Category 1 bulks list — substances evaluated and approved for compounding
- USP monograph — a pharmacopeia standard exists for the substance
- Component of an FDA-approved drug — typically only applies when the brand is in shortage
Neither semaglutide nor tirzepatide is on the Category 1 bulks list. Neither has a USP monograph. Their legal compounding relied exclusively on the third path — that they were components of shortage-designated drugs.
503B outsourcing facilities
Larger facilities that produce medications in bulk for hospitals and other providers. Similar rules but more stringent oversight.
What Changed in 2024-2025
The FDA officially removed tirzepatide from the shortage list in October 2024, and semaglutide in February 2025. Once shortage designation ended, the legal basis for compounding these specific medications narrowed significantly.
Some compounding pharmacies have argued that they can still compound under "clinical necessity" exceptions — e.g., a patient needs a different dose than what's commercially available, or is allergic to an inactive ingredient. This is a much narrower authorization than the shortage exception, and the FDA has been increasingly skeptical of its broad application.
FDA Enforcement Actions
The FDA has ramped up enforcement against compounded GLP-1 providers in 2025-2026:
- Warning letters to major telehealth platforms for "false or misleading claims" about compounded versions
- Product seizures from facilities found to be using unapproved chemical forms (e.g., semaglutide sodium instead of approved semaglutide)
- Investigations into reported dosing errors causing hospitalizations
- Notices of regulatory action against pharmacies selling "research chemicals" under the guise of clinical compounding
This doesn't mean every compounded GLP-1 is unsafe — legitimate compounders still exist. But it means the regulatory risk and quality variance is significantly higher than with brand-name medication.
The Pricing Math in 2026
Brand-name direct-pay pricing
In response to the shortage and competitive pressure, Eli Lilly and Novo Nordisk launched direct-to-consumer pharmacies with dramatically reduced cash-pay pricing:
- LillyDirect (launched 2024, expanded 2025-2026):
- Zepbound 2.5 mg: $299/mo
- Zepbound 5 mg: $499/mo
- Zepbound 7.5/10/12.5/15 mg: $499-549/mo depending on dose
- Foundayo (orforglipron, oral): $149-349/mo across doses
- NovoCare Pharmacy (Novo Nordisk's direct-pay):
- Wegovy 0.25-1 mg: $199/mo
- Wegovy 1.7-2.4 mg: $299-399/mo
Compounded pricing
- MEDVi compounded semaglutide: $179 first month, $299/mo recurring
- MEDVi compounded tirzepatide: $279 first month, $399-499/mo recurring
- Other compounders range broadly
The math comparison
For a patient starting on tirzepatide 2.5 mg for the first month:
- Compounded tirzepatide: $279-349 (varies by provider)
- Zepbound 2.5 mg via LillyDirect: $299
- Brand-name is cheaper or equal
For a patient on tirzepatide 10 mg maintenance:
- Compounded: $399-499/mo
- Zepbound via LillyDirect: $499-549/mo
- Compounded is slightly cheaper, $50-100/mo
For a patient on oral tirzepatide (Foundayo):
- Compounded oral tirzepatide: ~$299-399/mo
- Foundayo via LillyDirect: $149-349/mo
- Brand-name is typically cheaper
For a patient with insurance that covers Zepbound with savings card:
- Brand with savings card: $25/mo
- Compounded (insurance doesn't apply): $299+/mo
- Brand with insurance wins by a lot
Why Many Patients Still Choose Compounded
Even with pricing converged, several reasons explain the continued compounded volume:
- Awareness gap. Many patients don't realize LillyDirect and NovoCare Pharmacy exist or that prices dropped.
- Marketing saturation. MEDVi and similar platforms have massive SEO presence. Patients searching for "cheap GLP-1" land on them.
- Inertia. Switching costs feel higher than the modest savings delta.
- Custom dosing. Some patients legitimately need intermediate doses not available in brand form.
- Simplicity. Flat pricing, no insurance paperwork, familiar process. Brand-name with insurance involves more steps.
Why We Recommend Brand-Name
Valitide prescribes only FDA-approved brand-name GLP-1 medications — Zepbound, Foundayo, and Wegovy. Our rationale:
Regulatory durability. Brand-name medication is FDA-approved, manufactured under strict oversight, and not dependent on a regulatory window that could close. Compounded GLP-1s are in a contracting legal space.
Clinical evidence. Brand-name tirzepatide has the STEP and SURMOUNT trial data — tens of thousands of patients, rigorous efficacy and safety tracking. Compounded versions have no equivalent evidence base.
Pricing transparency. Whether you're using insurance or direct-pay, you know exactly what you'll pay. No surprise drug classifications, no billing disputes.
Dose consistency. Every injection contains the exact dose on the label. Compounded versions have had documented dosing errors.
Insurance optimization. If your insurance covers brand-name, we get you enrolled in savings programs that can drop your cost to $25/mo or less. That's not accessible with compounded.
Frequently Asked Questions
Is compounded GLP-1 illegal?
Not blanket illegal. 503A pharmacies can still compound in specific clinical-necessity scenarios. But the FDA has signaled enforcement concerns, and the broad cash-pay compounded model from 2023-2024 is no longer clearly legal under current rules. Pharmacies and providers operating in this space are taking on regulatory risk that didn't exist during the shortage window.
Is compounded GLP-1 safe?
Compounded medications from legitimate, FDA-registered 503A pharmacies are generally safe when prepared correctly. The risk factors are: (1) dosing errors in compounding, (2) unapproved chemical forms of the active ingredient, (3) contamination during production, and (4) inconsistent quality between batches. These risks are higher for compounded than for brand-name, but most compounders are careful.
What if I've had a good experience on compounded?
That's legitimate. Switching isn't mandatory — it's a decision based on your cost, access, and risk tolerance. If you're getting good results on a compounded regimen from a licensed pharmacy and are comfortable with the regulatory uncertainty, staying is a reasonable choice. Just don't assume compounded is always cheaper or safer.
If I switch to brand, do I lose my weight loss?
No. Brand and compounded contain the same active ingredient — tirzepatide is tirzepatide, semaglutide is semaglutide. Your biological response is the same. Most patients switch without any change in weight loss trajectory.
How long will compounded GLP-1s remain available?
Unclear. FDA could issue guidance documents significantly restricting patient-specific compounding. Some major compounders may exit the market voluntarily if regulatory pressure increases. Others will continue. The market is contracting, but there's no single cutoff date.
Making Your Decision
The right choice depends on your situation. Questions to ask yourself:
- Does my insurance cover brand-name Zepbound, Foundayo, or Wegovy? If yes, brand with savings card is almost certainly cheapest.
- Am I willing to pay $50-100/mo more for regulatory clarity? If yes, brand direct-pay is worth it.
- Am I on an unusual dose not available in brand? If yes, you may need to stay on compounded or work with your provider on an alternative.
- Am I comfortable with the FDA enforcement uncertainty? If no, brand.
For most patients in 2026, the math favors brand-name. That's why Valitide built its platform around it.
This guide is informational and not medical advice. Work with a licensed healthcare provider to determine the right medication and provider for your specific situation.